ABIVAX First-Half 2019 Financial Results and Operations Update
(WorldNews France)

Nine-month Phase 2a maintenance study confirmed further clinical improvements, with durability of efficacy and safety of ABX464 in ulcerative colitis patients One-year Phase 2a maintenance results including endoscopy to be reported during UEG week (October 19-23, Barcelona, Spain) ABX464 advanced into Phase 2b ulcerative colitis trial and Phase 2a rheumatoid arthritis trial ABX196 to move into Phase 1/2 trial in hepatocellular carcinoma EUR12m capital raised with Sofinnova in July 2019 Available funding sustains operations until end of Q2 2020 PARIS--(BUSINESS WIRE)--Sep. 19, 2019-- Regulatory News: This press release features multimedia. View the full release here:...